[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamic acid
• 化学式: C₂₂H₂₈FN₇O₄S
• 分子量: 505.6
• InChiKey: JPZUEBGWYRHEEO-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP2470526B1

  公开（公告）日：2014-05-28
• [EN] COMBINATION OF MDM2 INHIBITOR AND BRAF INHIBITOR AND THEIR USE<br/>[FR] COMBINAISON D'UN INHIBITEUR DE MDM2 ET D'UN INHIBITEUR DE BRAF, ET LEUR UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2015084804A1

  公开（公告）日：2015-06-11

  The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (i) a Mdm2 inhibitor and (ii) a BRAF inhibitor, or a pharmaceutically acceptable salt thereof, respectively, which are jointly active in the treatment of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carrier and related disclosure embodiments. In addition, the disclosure relates to the use of Mdm2 inhibitor in the treatment of colorectal cancer.